Monitoring response to treatment in the development of anti-cancer drugs using positron emission tomography (PET)

Drug Information Journal

Volumn 33, Issue 1, 1999, Pages 237-244

  Young, Helen ^a   Brock, Cathryn ^a   Wells, Paula ^a   Price, Pat ^a  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

Cancer therapy; Drug assessment; Positron imaging tomography

Indexed keywords

2 THYMIDINE C 11; ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOISOTOPE DISTRIBUTION; TUMOR VASCULARIZATION;

EID: 0033003753     PISSN: 00928615     EISSN: None     Source Type: Journal    
DOI: 10.1177/009286159903300126     Document Type: Article

References (41)

1. Miller AB, Hoogstraaten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981; 47:207-214.
2. Jones T. The role of positron emission tomography within the spectrum of medical imaging. Eur J Nucl Med. 1996;23:207-211.
3. Wilson MD. The study of blood flow and anti cancer agents in human tumours using positron emission tomography. MD thesis, 1992; University of London, UK.
4. Wilson CB, Snook DE, Dhokia B, Taylor CV, Watson IA, Lammertsma AA, Lambrecht R, Wakeman J, Jones T, Epenetos AA. Quantitative measurement of monoclonal antibody distribution and blood flow using positron emission tomography and 124-iodine in patients with breast cancer. Int J Cancer. 1991; 47(3):344-347.
5. Lammertsma AA. Positron emission tomography and in vivo measurements of tumour perfusion and oxygen utilisation. Cancer Metastasis Rev. 1987; 6(4):521-539.
6. Young H, Carnochan P, Zweit J, Babich J, Cherry S, Ott RJ. Evaluation of copper(,II)-pyruvaldehyde bis(N-4-methylthiosemicarbazone) for tissue blood flow measurement using a trapped tracer model. Eur J Nucl Med. 1994; 21:336-341
7. Jones T, Tilsley O, Wilson C, Lammertsma AA, Brown G, Brady F, Price P. Positron emission tomography for tumour assessment. NMR Biomed. 1992; 5:265-269.
8. Zweit J, Flower MA, Burke D, Davies H, Hall A, Mundy J, Young H, Carnochan P, Allen-Mersh T, Ott RJ. Clinical PET using a remote cyclotron: use of copper-62-PTSM in patients with colorectal liver metastases. J Nucl Med. 1996;37:54.
9. Young H, Zweit J, Burke D, Flower MA, Carnochan P, Mundy J, Hall A, Wells K, Ott RJ, McCready VR, Allen-Mersch. Quantifying tumour uptake of the blood flow tracer copper(II) pyruvaldehyde bis(N-4-methylthiosemicarbazone) (Cu-PTSM) with a multiwire proportional chamber positron camera. In: Faulkner K, Carey B, Crellin A, Harrsison RM, eds. Quantitative Imaging in Oncology. London: British Institute of Radiology; 1996;137-140.
10. Folkman J. Seminars in medicine of the Beth-Israel-Hospital, Boston - Clinical applications of research on angiogenesis. New Engl J Med. 1995;333(26): 1757-1763.
11. Teicher BA, Holden SA, Ara G, Sotomayer EA, Huang ZD, Chen YN, Brem H. Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents. Int J Cancer. 1994;57: 920-925.
12. Shields AF, Grierson LK, Krohn KA. Utilization of labelled thymidine in DNA synthesis: studies for PET. J Nucl Med. 1990;31(3):337-342.
13. Van Eijkeren, De Schryver A, Goethals P, Poupeye E, Schelstraete K, Lamahieu I, De-Potter CR. Measurement of short-term 11C-thymidine activity in human head and neck tumours using positron emission tomography. Acta Oncol. 1992;31(5);539-543.
14. Martial P, Ferrant A, Labar D, Cogneau M, Bol A, Michel C, Michaux JL, Sokal G. In vivo measurement of carbon-11 thymidine uptake in non-Hodgkin's lymphoma using positron emission tomography. J Nucl Med. 1988;29(10):1633-1637.
15. Vander Borght TM, Lambotte LE, Pauwels SA, Dive CC. Uptake of thymidine labelled on carbon 2: a potential index of liver regeneration by positron emission tomography. Hepatology. 1990;12(1):113-118.
16. Vander Borght TM, Lambotte LE, Pauwels SA, Labar D, Beckers C, Dive C. Non invasive measurement of liver regeneration with positron emission tomography and [2-11C]thymidine. Gastroenterol. 1991;101(3):794-799.
17. Cunningham V, Jones T. Spectral analysis of dynamic PET studies. J Cereb Blood Flow Metab. 1993;13:15-23.
18. 11C]-thymidine. Proc Am Soc Clin Onc. 1997: 16.
19. Gunn RN, Wells P, Cunningham V, Jones T, Price P. An investigation into the use of 2-[11C]-thymidine as a non-invasive index of cell proliferation in tumours in human studies using PET. Paans AMJ, Pruim J, Frannsen EJF, Vaalburg W, eds. Proceedings of the European Conference on Research and Applications of PET in Cancer. Groningen: PET Centrum; 1996:123-125.
20. Wells P, Gunn RN, Hughes A, Boddy A, Taylor GA, Rafi G, Price P, Newell GR. Thymidine salvage as a pharmacodynamic endpoint of thymidylate synthase inhibition in vivo. Proc Am Assoc Cancer Res. Philadelphia: American Association for Cancer Research; 1997;38:477.
21. Higashi T, Tamaki N, Honda T, Torizuka T, Kimura T, Inokuma T, Ohshio G, Hosotonic R, Imamura H, Konishi J. Expression of glucose transporters in human pancreatic tumours compared with increased FDG accumulation in PET study. J Nucl Med. 1997; 38:1337-1344.
22. Brown RS, Leung JY, Fisher SJ Frey KA, Ethier SP, Wahl RL. Intratumoral distribution of tritiated-FDG in breast cancer: correlation between Glut-1 expression and FDG uptake. J Nucl Med. 1996; 37(6):1042-1047.
23. Oya N, Nagata Y, Ishigaki T, Abe M, Tamaki N, Magata Y, Konishi J. Evaluation of experimental liver tumours using fluorine-18-2-fluoro-2-deoxy-D-glucose PET. J Nucl Med. 1993;34:2124-2129.
24. Wahl RL, Zasadny K, Helvie M, Hutchins GD, Weber B, Cody R. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography; initial evaluation. J Clin Oncol. 1993; 11(11):2101-2111.
25. Okada J, Yoshikawa K, Itami M, Imaseki K, Uno K, Itami J, Kuyama J, Mikata A, Arimizu N. Positron emission tomography using fluorine-18-fluorodeoxyglucose in malignant lymphoma; A comparison with proliferative activity. J Nucl Med. 1992;33:325-329.
26. Minn H, Paul R, Ahonen A, Klemi P. Fluorodeoxyglucose imaging: a method to assess the proliferative activity of human cancer in vivo. Comparison with DNA flow cytometry in head and neck tumours. Cancer. 1988;61:1776-1781.
27. Higashi K, Clavo AC, Wahl RL. Does FDG uptake measure proliferative activity of human cancer cell? In vitro comparison with DNA flow cytometry and tritiated thymidine uptake. J Nucl Med. 1993;34: 414-419.
28. 18F]-FDG metabolic imaging of tumours benefit oncology? Eur J Nucl Med. 1997;24:691-705.
29. Hughes JMB. 18F-fluorodeoxyglucose PET scans in Lung Cancer. Thorax. 1996;51:516-522.
30. Gupta H, Bradfield H. Role of positron emission tomography in evaluating gastrointestinal neoplasms. Semin Nucl Med. 1996;26(1):65-73.
31. Stevens AW, Gonin R, Hutchins GD, Einhorn LH. Positron emission tomography evaluation of residual radiographic abnormalities in post chemotherapy germ cell tumour patients. J Clin Oncol. 1996;14(5): 1637-1641.
32. Findlay M, Young H, Cunningham D, Iveson A, Cronin B, Hikish T, Pratt B, Husband J, Flower M, Ott RJ. Non invasive monitoring of tumour metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumour response to fluorouracil. J Clin Oncol. 1996;14(3):700-708.
33. Jansson T, Westlin JE, Ahlstrom H, Lija B, Langstrom B, Bergh J. Positron emission tomography studies in patients with locally advanced and/or metatstatic breast cancer: A method for early therapy evaluation. J Clin Oncol. 1995;13:1460-1477.
34. Hoekstra OS, Ossenkoppele GJ, Golding R, Van-Lingen A, Visser GW, Teule GJ, Huijgens PC. Early treatment response in malignant lymphomas, as determined by planer fluorine-18-fluorodeoxyglucose scintigraphy. J Nucl Med. 1993;34:1706-1710.
35. Haberkorn U, Strauss LG, Dimitrakopoulou A, Seiffert E, Oberdorfer F, Ziegler S, Reisser C, Doll J, Helus F, Van Kuick G. Fluorodeoxyglucose imaging of advanced head and neck cancer after chemotherapy. J Nucl Med. 1993;34(1):12-17.
36. Newlands ES, Stevens MF, Wedge SR, Wheelhouse RT, Brock C. Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev. 1977;23:35-61.
37. O'Reilly SM, Harte RJA, Newlands ES, Jones T, Price P. Early changes in tumour glucose metabolism may predict and quantify response of gliomas to chemotherapy: a Phase II study using Temozolomide. Proceedings of the American Society of Clinical Oncology. Chicago: American Society of Clinical Oncology; 1995;14:499.
38. Hamberg LM, Hunter GJ, Alpert NM, Choi NC, Babich JW, Fischman AJ. The dose uptake ratio as an index of glucose metabolism: useful parameter or oversimplification? J Nucl Med. 1994;35(8): 1308-1312.
39. Eberl S, Anayat A, Fulton R, Hooper PK, Fulham MJ. Evaluation of two population-based input functions for quantitative neurological studies. Eur J Nucl Med. 1997;24:299-304.
40. Haberkorn U, Strauss LG, Dimitrakopoulou A, Seiffert E, Oberdorfer F, Ziegler S, Reisser C, Doll J, Helus F, Van Kuick G. PET studies of fluorodeoxyglucose metabolism in patients with colorectal tumours receiving radiotherapy. J Nucl Med. 1991;32: 1485-1490.
41. Price P, Jones T. Can positron emission tomography (PET) be used to detect sub clinical response to cancer therapy? Eur J Cancer. 1995;31A(12):1924-1927.